Item 2.02 - Results of Operations and Financial Condition: The filing reports financial results and operational performance for Intuitive Surgical, Inc. Item 9.01 - Financial Statements and Exhibits: The filing includes financial statements and exhibits related to the reported results. Filing Date: January 14, 2026 - this is a current report filed on the same date as the earliest event reported.…

Our analysis rates this filing NEUTRAL. Intuitive Surgical presents a balanced, stable picture with moderate concerns offset by strong fundamentals. The company delivered robust 21% revenue growth and 19% procedure volume growth in 2025, demonstrating continued market strength and execution…

Concern level: MODERATE (3.2/10). Key factors: Ion system placement decline of 39% YoY (Q4: 42 units vs 69 prior year) signals slower-than-expected adoption of emerging product platform; 2026 da Vinci procedure growth guidance of 13-15% represents material deceleration from 18% actual 2025 growth, suggesting potential market normalization or competitive headwinds; Ion platform execution risk on…

Notable risk changes: Ion system placement momentum loss: Q4 2025 placements of 42 units down 39% from 69 units in Q4 2024, suggesting slower adoption of endoluminal platform than prior trajectory; 2026 procedure growth guidance of 13-15% represents material deceleration from 18% actual 2025 growth, signaling potential market headwinds or normalization after strong 2025; No material negative events disclosed: Filing…

No earnings surprise data disclosed in this 8-K filing.

The model predicts ISRG will outperform the S&P 500 by about 0.0% over 30 days (model confidence 50%). This is model analysis for research, not investment advice.